HEALTH TECHNOLOGY ASSESSMENTS OF BEVACIZUMAB BIOSIMILARS: COULD A DEMONSTRATION OF COST-EFFECTIVENESS CHANGE THE RECOMMENDATION FOR REIMBURSEMENT VERSUS THE ORIGINATOR?

被引：1
|
作者：
Hnoosh, A. [1 ]
Courmier, D. F. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1134
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP240
引用
收藏
页码：S191 / S191
页数：1
相关论文
共 17 条
  • [1] TRENDS IN HEALTH TECHNOLOGY ASSESSMENTS SINCE THE INTRODUCTION OF COST-EFFECTIVENESS IN THE NETHERLANDS
    Dvortsin, E.
    Vondeling, G.
    van der Woude, T.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A833 - A833
  • [2] Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis
    Postma, Maarten J.
    Boersma, Cornelis
    Vandijck, Dominique
    Vegter, Stefan
    Le, Hoa H.
    Annemans, Lieven
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (04) : 367 - 369
  • [3] Subgroup analyses in cost-effectiveness analyses to support health technology assessments
    Fletcher, Christine
    Chuang-Stein, Christy
    Paget, Marie-Ange
    Reid, Carol
    Hawkins, Neil
    [J]. PHARMACEUTICAL STATISTICS, 2014, 13 (04) : 265 - 274
  • [4] HEALTH TECHNOLOGY ASSESSMENTS REPORTING COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION
    Kularatna, Sanjeewa
    Byrnes, Joshua
    Mervin, Merehau Cindy
    Scuffham, Paul A.
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2016, 32 (03) : 89 - 96
  • [5] Reviewing the Evidence to Inform the Population of Cost-Effectiveness Models within Health Technology Assessments
    Kaltenthaler, Eva
    Tappenden, Paul
    Paisley, Suzy
    [J]. VALUE IN HEALTH, 2013, 16 (05) : 830 - 836
  • [6] Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers
    Schwarze, Juan-Enrique
    Venetis, Christos
    Iniesta, Silvia
    Falla, Edel
    Lukyanov, Vasily
    Calvo, Elena de Agustin
    D 'Hooghe, Thomas
    Roeder, Claudia
    Matorras, Roberto
    [J]. BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2022, 85 : 203 - 216
  • [7] A SYSTEMATIC LITERATURE REVIEW OF RATIONALE, METHODS, AND USE OF COST-EFFECTIVENESS THRESHOLDS IN HEALTH TECHNOLOGY ASSESSMENTS
    Basarir, H.
    Mauskopf, J.
    McCrink, L.
    Karmarkar, T.
    O'Brien, M.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S330 - S331
  • [8] A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis
    Iannazzo, Sergio
    De Francesco, Maria
    Gomez-Ulloa, David
    Benucci, Maurizio
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (04) : 455 - 468
  • [9] AN ANALYSIS OF THE HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATION AND GUIDANCE ON USE OF EQ-5D-5L IN COST-EFFECTIVENESS MODELING
    Ovcinnikova, O.
    Firth, Z. A.
    Dimova, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A573 - A574
  • [10] Evidence synthesis to inform model-based cost-effectiveness evaluations of diagnostic tests: a methodological review of health technology assessments
    Bethany Shinkins
    Yaling Yang
    Lucy Abel
    Thomas R. Fanshawe
    [J]. BMC Medical Research Methodology, 17
12